SciVision Biotech Inc (1786) - Total Liabilities
Based on the latest financial reports, SciVision Biotech Inc (1786) has total liabilities worth NT$689.27 Million TWD (≈ $21.72 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 1786 operating cash flow to assess how effectively this company generates cash.
SciVision Biotech Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how SciVision Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Check 1786 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
SciVision Biotech Inc Competitors by Total Liabilities
The table below lists competitors of SciVision Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RCM Technologies Inc
NASDAQ:RCMT
|
USA | $88.44 Million |
|
Lindsell Train Investment Trust Plc
LSE:LTI
|
UK | £209.00K |
|
Waterco Ltd
AU:WAT
|
Australia | AU$121.60 Million |
|
Hiap Teck Venture Bhd
KLSE:5072
|
Malaysia | RM585.24 Million |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
USA | $954.51 Million |
|
BARK, Inc.
NYSE:BARK
|
USA | $107.42 Million |
|
Comet Ridge Ltd
AU:COI
|
Australia | AU$44.68 Million |
|
Rhinebeck Bancorp Inc
NASDAQ:RBKB
|
USA | $1.16 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down SciVision Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SciVision Biotech Inc (1786) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SciVision Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SciVision Biotech Inc (2009–2024)
The table below shows the annual total liabilities of SciVision Biotech Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$457.43 Million ≈ $14.41 Million |
-14.29% |
| 2023-12-31 | NT$533.66 Million ≈ $16.81 Million |
-9.13% |
| 2022-12-31 | NT$587.30 Million ≈ $18.50 Million |
-27.68% |
| 2021-12-31 | NT$812.06 Million ≈ $25.58 Million |
+66.90% |
| 2020-12-31 | NT$486.55 Million ≈ $15.33 Million |
-2.90% |
| 2019-12-31 | NT$501.08 Million ≈ $15.79 Million |
-18.88% |
| 2018-12-31 | NT$617.70 Million ≈ $19.46 Million |
-4.78% |
| 2017-12-31 | NT$648.72 Million ≈ $20.44 Million |
+40.13% |
| 2016-12-31 | NT$462.93 Million ≈ $14.58 Million |
+272.86% |
| 2015-12-31 | NT$124.16 Million ≈ $3.91 Million |
+80.43% |
| 2014-12-31 | NT$68.81 Million ≈ $2.17 Million |
+52.13% |
| 2013-12-31 | NT$45.23 Million ≈ $1.43 Million |
-21.07% |
| 2012-12-31 | NT$57.31 Million ≈ $1.81 Million |
+42.67% |
| 2011-12-31 | NT$40.17 Million ≈ $1.27 Million |
-63.89% |
| 2010-12-31 | NT$111.24 Million ≈ $3.50 Million |
+6.64% |
| 2009-12-31 | NT$104.31 Million ≈ $3.29 Million |
-- |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more